Shanghai Hi-Tech United Biological Technology Research Development

Shanghai Hi-Tech United Bio-Technological Research & Development is a Chinese biotechnology company focused on developing novel anti-infective biological therapies to address bacterial resistance. A key focus of the company is the development of recombinant lysostaphin (rLysostaphin), a peptidoglycan hydrolase that specifically targets and lyses Staphylococcus aureus, including methicillin-resistant strains (MRSA). The company's recombinant lysostaphin program has progressed to Phase 3 clinical trials in China for the treatment of S. aureus infections in deep burn wounds. The company operates as a subsidiary of Shanghai Hi-Tech Bio-Engineering, leveraging its parent company's GMP-compliant manufacturing capabilities and commercial network.